Analysts Set Expectations for SNDX Q3 Earnings

Key Points

• B. Riley forecasts Syndax Pharmaceuticals will report a Q3 2025 EPS of ($0.68), maintaining a "Strong-Buy" rating on the stock.
• The company reported a 984.5% increase in revenue year-over-year for the last quarter, with earnings per share of ($0.83), surpassing analyst estimates.
• Analysts have varied target prices for Syndax Pharmaceuticals, with Citigroup raising their price target from $46 to $51 while maintaining a "buy" rating.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Equities researchers at B. Riley issued their Q3 2025 earnings estimates for Syndax Pharmaceuticals in a research report issued to clients and investors on Wednesday, August 6th. B. Riley analyst M. Mamtani forecasts that the company will post earnings of ($0.68) per share for the quarter. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for Syndax Pharmaceuticals' current full-year earnings is ($3.72) per share. B. Riley also issued estimates for Syndax Pharmaceuticals' Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.99) EPS, FY2026 earnings at ($1.16) EPS and FY2027 earnings at $0.12 EPS.

Several other analysts also recently issued reports on the company. Citigroup boosted their price objective on Syndax Pharmaceuticals from $46.00 to $51.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. Guggenheim restated a "buy" rating and set a $32.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, May 6th. UBS Group cut their price objective on Syndax Pharmaceuticals from $37.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, July 15th. Wall Street Zen upgraded Syndax Pharmaceuticals to a "sell" rating in a report on Tuesday, May 6th. Finally, Scotiabank boosted their price objective on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a report on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $36.91.

Syndax Pharmaceuticals Trading Up 3.6%

NASDAQ SNDX traded up $0.46 on Friday, hitting $12.97. 1,315,347 shares of the company were exchanged, compared to its average volume of 2,228,369. The company's 50 day moving average price is $10.11 and its 200-day moving average price is $11.86. The company has a debt-to-equity ratio of 2.06, a current ratio of 4.71 and a quick ratio of 4.55. The firm has a market capitalization of $1.12 billion, a P/E ratio of -3.34 and a beta of 0.74. Syndax Pharmaceuticals has a twelve month low of $8.58 and a twelve month high of $22.50.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.01) by $0.18. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The firm had revenue of $37.96 million for the quarter, compared to analysts' expectations of $26.64 million. During the same period in the previous year, the business earned ($0.80) earnings per share. Syndax Pharmaceuticals's revenue for the quarter was up 984.5% compared to the same quarter last year.

Insiders Place Their Bets

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 7,534 shares of Syndax Pharmaceuticals stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $9.29, for a total transaction of $69,990.86. Following the transaction, the chief executive officer owned 298,661 shares of the company's stock, valued at $2,774,560.69. The trade was a 2.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Rhumbline Advisers grew its stake in shares of Syndax Pharmaceuticals by 6.6% in the 2nd quarter. Rhumbline Advisers now owns 128,732 shares of the company's stock valued at $1,206,000 after buying an additional 7,922 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Syndax Pharmaceuticals by 14.5% in the 2nd quarter. Franklin Resources Inc. now owns 2,359,677 shares of the company's stock valued at $22,098,000 after buying an additional 298,272 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Syndax Pharmaceuticals by 4.9% in the 2nd quarter. Legal & General Group Plc now owns 84,575 shares of the company's stock valued at $792,000 after buying an additional 3,937 shares in the last quarter. DNB Asset Management AS grew its stake in shares of Syndax Pharmaceuticals by 31.2% in the 2nd quarter. DNB Asset Management AS now owns 29,362 shares of the company's stock valued at $275,000 after buying an additional 6,984 shares in the last quarter. Finally, Swiss National Bank grew its stake in shares of Syndax Pharmaceuticals by 10.0% in the 2nd quarter. Swiss National Bank now owns 164,300 shares of the company's stock valued at $1,539,000 after buying an additional 14,900 shares in the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).